Novo Nordisk: to present progress in hematology
(CercleFinance.com) - Novo Nordisk announces the presentation of 13 abstracts at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held in San Diego from 7 to 10 December 2024.
Amongst the presentations, the 52-week results of the phase 2/3 HIBISCUS trial on etavopivat will be presented on 7 December, highlighting its efficacy and safety for the treatment of sickle cell disease.
In addition, two oral presentations concern the FRONTIER4 and explorer7 studies on Mim8 and concizumab, respectively, for the treatment of hemophilia A with and without inhibitors.
Martin Holst Lange, Executive Vice President of Novo Nordisk, emphasized the importance of this research in addressing the unmet needs of patients with rare blood disorders.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Amongst the presentations, the 52-week results of the phase 2/3 HIBISCUS trial on etavopivat will be presented on 7 December, highlighting its efficacy and safety for the treatment of sickle cell disease.
In addition, two oral presentations concern the FRONTIER4 and explorer7 studies on Mim8 and concizumab, respectively, for the treatment of hemophilia A with and without inhibitors.
Martin Holst Lange, Executive Vice President of Novo Nordisk, emphasized the importance of this research in addressing the unmet needs of patients with rare blood disorders.
Copyright (c) 2024 CercleFinance.com. All rights reserved.